Search results
Results from the WOW.Com Content Network
Pitolisant is indicated in adults for the treatment of narcolepsy. [3] [4] Narcolepsy is a chronic sleep disorder that causes overwhelming daytime drowsiness. [4] Pitolisant is also indicated to improve alertness and reduce excessive daytime sleepiness in adults with obstructive sleep apnea. [5] [12]
Narcolepsy is a chronic neurological disorder that impairs the ability to regulate sleep–wake cycles, and specifically impacts REM (rapid eye movement) sleep. [1] The pentad symptoms of narcolepsy include excessive daytime sleepiness (EDS), sleep-related hallucinations, sleep paralysis, disturbed nocturnal sleep (DNS), and cataplexy. [1]
Pitolisant has been shown to be effective and well-tolerated for the treatment of narcolepsy with or without cataplexy. [181] [180] [179] Pitolisant is the only non-controlled anti-narcoleptic drug in the US. [179] It has shown minimal abuse risk in studies. [179] [182]
Pediatric narcolepsy cases are cases when patients are diagnosed or experience symptoms onset for narcolepsy before the age of 18. Of patients who obtain a formal diagnosis for narcolepsy, more than 50% report first experiencing symptoms of narcolepsy more than 10 years before their formal diagnosis, with an average age of symptom onset being at age 15 and symptom onset most likely to occur ...
This condition was first discovered in 1995 by Melberg et al. when they described 5 members of a 4-generation Swedish family where cerebellar ataxia and sensorineural deafness presented as an autosomal dominant trait, 4 of them had narcolepsy and 2 had diabetes mellitus. The oldest members had psychiatric symptoms, neurological anomalies, and ...
Around 70% of patients with narcolepsy also experience cataplexy episodes, according to U.S. government data, which can cause slurred speech or muscle weakness triggered by intense emotions.
Solriamfetol is used to promote wakefulness in the treatment of excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea in adults. [1] It appears to be more effective in improving excessive daytime sleepiness associated with obstructive sleep apnea than certain other wakefulness-promoting agents including modafinil, armodafinil, and pitolisant.
Amphetamine type stimulants can be used in the treatment of narcolepsy, a rare neurological disorder where the brain is unable to regulate the sleep-wake mechanism. [17] Amphetamines causes an increase in dopamine release, which is the proposed mechanism for its wake-promoting effect. [ 18 ]